INOVIO to Present at Upcoming Scientific Conferences
INOVIO (NASDAQ:INO) has announced its participation in several upcoming scientific conferences to present data on its lead candidate INO-3107 and DNA medicine technologies. At the National HPV Conference in Indianapolis on April 15, the company will present results showing a 72% overall response rate in Year 1 for treating Recurrent Respiratory Papillomatosis caused by HPV-6 & 11.
The company will also participate in the World Vaccine Congress in Washington, DC (April 21-23), where they will discuss their DNA-encoded monoclonal antibody (DMAb™) technology and DNA immunotherapeutics for cancer and viral diseases. Additionally, INOVIO will present at the Festival of Biologics in San Diego on April 23, focusing on INO-3107 for Recurrent Respiratory Papillomatosis. Abstracts will be available on INOVIO's website after the presentations.
INOVIO (NASDAQ:INO) ha annunciato la sua partecipazione a diverse conferenze scientifiche in arrivo per presentare dati sul suo candidato principale INO-3107 e sulle tecnologie della medicina DNA. Alla Conferenza Nazionale HPV a Indianapolis il 15 aprile, l'azienda presenterà risultati che mostrano un tasso di risposta complessivo del 72% nel Primo Anno per il trattamento della Papillomatosi Respiratoria Ricorrente causata da HPV-6 e 11.
L'azienda parteciperà anche al World Vaccine Congress a Washington, DC (21-23 aprile), dove discuterà della sua tecnologia di anticorpi monoclonali codificati da DNA (DMAb™) e degli immunoterapici a base di DNA per il cancro e le malattie virali. Inoltre, INOVIO presenterà al Festival of Biologics a San Diego il 23 aprile, concentrandosi su INO-3107 per la Papillomatosi Respiratoria Ricorrente. Gli abstract saranno disponibili sul sito web di INOVIO dopo le presentazioni.
INOVIO (NASDAQ:INO) ha anunciado su participación en varias conferencias científicas próximas para presentar datos sobre su candidato principal INO-3107 y las tecnologías de medicina de ADN. En la Conferencia Nacional de VPH en Indianápolis el 15 de abril, la empresa presentará resultados que muestran una tasa de respuesta general del 72% en el Primer Año para el tratamiento de Papilomatosis Respiratoria Recurrente causada por VPH-6 y 11.
La empresa también participará en el World Vaccine Congress en Washington, DC (21-23 de abril), donde discutirán su tecnología de anticuerpos monoclonales codificados por ADN (DMAb™) y los inmunoterapéuticos de ADN para el cáncer y enfermedades virales. Además, INOVIO presentará en el Festival de Biológicos en San Diego el 23 de abril, centrándose en INO-3107 para la Papilomatosis Respiratoria Recurrente. Los resúmenes estarán disponibles en el sitio web de INOVIO después de las presentaciones.
INOVIO (NASDAQ:INO)는 주요 후보인 INO-3107 및 DNA 의학 기술에 대한 데이터를 발표하기 위해 다가오는 여러 과학 회의에 참여할 것이라고 발표했습니다. 4월 15일 인디애나폴리스에서 열리는 국가 HPV 회의에서 이 회사는 HPV-6 및 11로 인한 재발성 호흡기 유두종증 치료를 위한 1년 차 전체 반응률이 72%라는 결과를 발표할 예정입니다.
이 회사는 또한 4월 21일부터 23일까지 워싱턴 DC에서 열리는 World Vaccine Congress에 참여하여 DNA로 인코딩된 단클론 항체(DMAb™) 기술 및 암과 바이러스 질병을 위한 DNA 면역치료제에 대해 논의할 것입니다. 또한 INOVIO는 4월 23일 샌디에이고에서 열리는 생물학 축제에서 재발성 호흡기 유두종증에 대한 INO-3107에 집중하여 발표할 것입니다. 발표 후 INOVIO의 웹사이트에서 초록을 확인할 수 있습니다.
INOVIO (NASDAQ:INO) a annoncé sa participation à plusieurs conférences scientifiques à venir pour présenter des données sur son candidat principal INO-3107 et sur les technologies de médecine ADN. Lors de la Conférence Nationale sur le VPH à Indianapolis le 15 avril, l'entreprise présentera des résultats montrant un taux de réponse global de 72 % au cours de la première année pour le traitement de la Papillomatose Respiratoire Récurrente causée par le VPH-6 et 11.
L'entreprise participera également au World Vaccine Congress à Washington, DC (21-23 avril), où elle discutera de sa technologie d'anticorps monoclonaux codés par ADN (DMAb™) et des immunothérapies à base d'ADN pour le cancer et les maladies virales. De plus, INOVIO présentera au Festival of Biologics à San Diego le 23 avril, en se concentrant sur INO-3107 pour la Papillomatose Respiratoire Récurrente. Les résumés seront disponibles sur le site Web d'INOVIO après les présentations.
INOVIO (NASDAQ:INO) hat seine Teilnahme an mehreren bevorstehenden wissenschaftlichen Konferenzen angekündigt, um Daten zu seinem Hauptkandidaten INO-3107 und DNA-Medizin-Technologien zu präsentieren. Auf der Nationalen HPV-Konferenz in Indianapolis am 15. April wird das Unternehmen Ergebnisse präsentieren, die eine Gesamtansprechrate von 72 % im ersten Jahr für die Behandlung von wiederkehrender Atemwegspapillomatose, die durch HPV-6 und 11 verursacht wird, zeigen.
Das Unternehmen wird auch am World Vaccine Congress in Washington, DC (21.-23. April) teilnehmen, wo sie ihre DNA-kodierte monoklonale Antikörper-Technologie (DMAb™) und DNA-Immuntherapeutika für Krebs und Viruskrankheiten diskutieren werden. Darüber hinaus wird INOVIO am 23. April beim Festival of Biologics in San Diego präsentieren und sich auf INO-3107 für wiederkehrende Atemwegspapillomatose konzentrieren. Abstracts werden nach den Präsentationen auf der Website von INOVIO verfügbar sein.
- None.
- None.
National HPV Conference (
April 15:
- Oral presentation: DNA Immunotherapy (INO-3107) Results in a
72% Overall Response Rate in Year 1 for Treatment of Recurrent Respiratory Papillomatosis Caused by HPV-6 & 11 - Panel: Recurrent Respiratory Papillomatosis: Lessons Learned, Clinical Advances and Patient Experiences – Moderated by Kim McClellan, RRP Foundation President
World Vaccine Congress (
April 21:
- Oral presentation: A New Frontier in mAb Therapeutics: DNA-Encoded Monoclonal Antibodies (DMAb™) as Next Gen DNA Medicine
April 23:
- Oral presentation: DNA Immunotherapeutics in the Treatment of Cancers and Virally-Mediated Diseases
Festival of Biologics (
April 23:
- Oral presentation: Advancing DNA Medicine: INO-3107 for Recurrent Respiratory Papillomatosis
Available abstracts will be shared on INOVIO's website following presentations.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conferences-302424147.html
SOURCE INOVIO Pharmaceuticals, Inc.
FAQ
What is the success rate of INOVIO's INO-3107 treatment for RRP?
Which scientific conferences will INOVIO (INO) present at in April 2025?
What new technology will INOVIO showcase at the World Vaccine Congress 2025?
What diseases does INOVIO's DNA medicine portfolio target?
When will INOVIO's presentation abstracts be available to the public?
